GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Tissue Regenix Group PLC (LSE:TRX) » Definitions » Buyback Yield %

Tissue Regenix Group (LSE:TRX) Buyback Yield % : 0.00 (As of Jun. 04, 2024)


View and export this data going back to 2006. Start your Free Trial

What is Tissue Regenix Group Buyback Yield %?

Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.

Tissue Regenix Group's current buyback yield was 0.00%.


Tissue Regenix Group Buyback Yield % Historical Data

The historical data trend for Tissue Regenix Group's Buyback Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Tissue Regenix Group Buyback Yield % Chart

Tissue Regenix Group Annual Data
Trend Jan14 Jan15 Jan16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Buyback Yield %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.01 -36.57 - -0.02 -0.16

Tissue Regenix Group Semi-Annual Data
Jan14 Jul14 Jan15 Jul15 Jan16 Jul16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Buyback Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - -0.04 - - -

Competitive Comparison of Tissue Regenix Group's Buyback Yield %

For the Biotechnology subindustry, Tissue Regenix Group's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Tissue Regenix Group's Buyback Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Tissue Regenix Group's Buyback Yield % distribution charts can be found below:

* The bar in red indicates where Tissue Regenix Group's Buyback Yield % falls into.



Tissue Regenix Group Buyback Yield % Calculation

Buyback yield is a measure of shareholder return.

Tissue Regenix Group's Buyback Yield for the fiscal year that ended in Dec. 2023 is calculated as

Buyback Yield=Net Issuance of Stock / Market Cap
=- (Repurchase of Stock + Issuance of Stock) / Market Cap
=- (0 + 0.058) / 36.69874
=-0.16%

Tissue Regenix Group's annualized Buyback Yield for the quarter that ended in Dec. 2023 is calculated as

Buyback Yield=Net Issuance of Stock(Annualized) / Market Cap
=- (Repurchase of Stock + Issuance of Stock) * Annualized Factor / Market Cap
=- (0 + 0) * 2 / 36.69874
=0.00%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In calculating the annualized semi-annual data, the Repurchase of Stock and Issuance of Stock data used here is two times the semi-annual (Dec. 2023) data.


Tissue Regenix Group Buyback Yield % Related Terms

Thank you for viewing the detailed overview of Tissue Regenix Group's Buyback Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.


Tissue Regenix Group (LSE:TRX) Business Description

Traded in Other Exchanges
Address
Lotherton Way, Unit 3, Phoenix Court, Garforth, GBR, LS25 2GY
Tissue Regenix Group PLC is a pioneering medical technology company engaged in the development of regenerative products. The company incorporates dCELL and BioRinse technology, which helps to address complex and varying clinical needs. Its product portfolio includes Biosurgery, Orthopaedics, and Dental. The company has operations around the world, with special emphasis in the United States.

Tissue Regenix Group (LSE:TRX) Headlines

From GuruFocus

Doubling of Gold Mineral Resources Confirmed

By GlobeNewswire GlobeNewswire 06-23-2020

Tanzanian Royalty Announces the Sale of Common Shares of $885,734

By GlobeNewswire GlobeNewswire 01-13-2019

TanGold Announces Board and Management Change

By GlobeNewswire GlobeNewswire 01-21-2021